北京脚底突发痛风怎么治疗(济南老人脚上痛风怎么办) (今日更新中)

BERLIN, June 14 (Xinhua) -- A two-year-old boy became the first child to be killed by the deadly E. coli in Germany on Tuesday, officials said.To date, the terrifying EHEC infection has claimed 36 lives in Germany and one in Sweden.The child, from the northern town of Celle, died in hospital in Hanover of kidney failure and abnormal breakdown of red blood cells, two extreme symptoms of the infection with enterohaemorrhagic E. coli (EHEC), authorities in the state of Lower Saxony said.The boy became the youngest known fatal victim since the outbreak of E. coli in May. His father and 10-year-old brother were also infected with the deadly bacteria, but are recovering, doctors told a local newspaper.The Robert Koch Institute, Germany's national disease prevention and control agency, said on Tuesday that a total of 3, 235 cases had been reported in the country. Among them, 782 people are suffering from haemolytic uraemic syndrome (HUS), a life- threatening illness arising from E. coli, which would destroy human kidney and nervous system.The institute added that the number of new infections is declining sharply in recent days, with only seven reported on Tuesday.German authorities announced on Friday that bean sprouts from a farm in northern Germany were one source of the outbreak, and dropped the previous warning against eating raw cucumbers, tomatoes and lettuce. However, the food panic has caused losses worth hundreds of millions of dollars for European farmers.

SINGAPORE, Sept. 7 (Xinhua) -- Singapore scientists have found possible new ways to treat a type of aggressive breast cancer that is unresponsive to current forms of treatment, local broadcaster Channel NewsAsia reported on Wednesday.The team of scientists at the Genome Institute of Singapore ( GIS) and National University of Singapore (NUS), led by GIS senior group leader Qiang Yu, found that the enzyme EZH2 acts by inhibiting genes that stop the growth of tumors in the body.The insights could open the door to developing more effective treatment for fast spreading breast cancers, especially the estrogen receptor-negative breast cancer that is common all over the world.It was also found that through EZH2, cancer is promoted in the body by activating specific genes that impact breast cancer progression and cancer stem cell self-renewal.Yu said the new understanding on how EZH2 works as a cancer- causing gene in breast cancer has important therapeutic implication."The results suggest that small molecule drugs that block enzyme activity of EZH2 may not work for cancers caused by EZH2's activation genes," Yu said.Currently pharmaceutical companies have been developing drugs only to the block EZH2 enzyme activity so that tumor suppressers can perform their protective role in blocking cancer growth.Researchers said the next step would be to develop biomarkers to identify tumors with EZH2.This step would enable better treatment methods, with one of options being the development of therapies that shut down EZH2 completely and not just inhibit its enzymatic function.The findings have been published on the journal Molecular Cell.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, July 20 (Xinhuanet) -- Some U.S. soldiers returning from the Middle East have acquired constrictive bronchiolitis, a kind of lung damage virtually unknown in young adults, according to U.S. News & World Report."Respiratory disorders are emerging as a major consequence of service in southwest Asia," said study author Dr. Matthew S. King, an assistant professor of pulmonary and critical care at Meharry Medical College in Nashville, Tenn."In addition to our study, there have been studies showing increases in asthma, obstructive lung disease, allergic rhinitis and a general increase in reports of respiratory symptoms," he added. "Most of the patients say they can’t seem to catch their breath when exerting themselves."On the other hand, Anthony Szema, a physician and engineer at Stony Brook University in New York, has examined a soldier and found tiny complexes of titanium and iron in the man’s lungs, where metals can cause severe damage.Mined separately, the two metals could have gotten together only through a manufacturing process, Szema reported. While the metals’ origin is unclear, he presents a new case study, suspecting garbage-burning pits or exploding devices sent them airborne.While the cases in the study represent only a few dozen people of the hundreds of thousands serving in the Middle East, there is no estimate of how many more might have bronchiolitis.it is recommended that soldiers exercise caution in the field until more is known. Soldiers are now told to wear a mask when burning garbage.

SAN FRANCISCO, July 28 (Xinhua) -- Global marketing and advertising research company Nielson on Thursday said in its latest survey that Google's Android operating system (OS) continued to dominate the U.S. smartphone market in June.According to Nielson's June survey of mobile consumers, the Android OS claims the largest share of the U.S. consumer smartphone market with 39 percent. Apple's iOS is in second place with 28 percent while RIM Blackberry is down to 20 percent.Microsoft's Windows Phone 7 OS had a 9 percent share of the market while HP webOS (Palm) accounted for 2 percent as did Nokia' s Symbian.In Nielson's May survey, 38 percent of smartphone consumers had a device powered by Android, compared to 27 percent for Apple's iOS for iPhones and 21 percent for RIM Blackberry.Talking about the manufacturer share, Apple is the No.1 in the U.S. as it is the only company manufacturing smartphones with the iOS, said the report.Other leading manufacturers include HTC, whose Android phones represents 14 percent of the smartphone market and whose Windows Mobile/WP7 devices accounted for 6 percent of the market.Motorola's Android devices are owned by 11 percent of smartphone consumers. Samsung's Android devices are used by 8 percent of smartphone consumers and its Windows Phone 7 devices take a 2 percent share, said Nielson.

来源：资阳报